– This is an important agreement for us at IFE, as we want to be a preferred partner for the Norwegian early-stage environment in cancer research, and specifically in the field of radioactive drugs. We take on this distribution assignment with great respect for the responsibility that lies in securing cancer patients all over the world temporarily and predictably access to innovative treatment options with radioactive drugs, comments IFE Division Director Erik Flatmark, Radiopharmacy.
Radspherin® is a Radium-224 based drug that is under development and is expected to potentially treat several forms of metastatic cancer. – The agreement with IFE is an important part of our infrastructure, and allows us to offer patients to participate in the clinical trial program with access to Radspherin in a timely and predictable manner without geographical boundaries, Jan A. Alfheim, Oncoinvent’s CEO said.
Related news
-
27. May 2025
The Norwegian solar power community gathers for two important events
This week, the Norwegian solar power (PV) community was gathered in sunny Son for two…
-
16. May 2025
Press release: ECOPEM project launches to deliver next-generation, non-fluorinated components for fuel cells and electrolysers
Lillestrøm, 12 May 2025 The Horizon Europe project ECOPEM (dEvelopment of…